Filing Details
- Accession Number:
- 0000899243-18-027478
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-10-25 18:25:33
- Reporting Period:
- 2018-10-23
- Accepted Time:
- 2018-10-25 18:25:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1664106 | Logicbio Therapeutics Inc. | LOGC | Biological Products, (No Disgnostic Substances) (2836) | 471514975 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1752486 | Sofia Ioannidou | C/O Logicbio Therapeutics, Inc. 610 Main St., 3Rd Floor Cambridge MA 02139 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-10-23 | 1,367,413 | $0.00 | 1,367,413 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2018-10-23 | 420,000 | $10.00 | 1,787,413 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Convertible Preferred Stock | Disposition | 2018-10-23 | 2,611,665 | $0.00 | 1,367,413 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect |
Footnotes
- Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock.
- The Reporting Person is a director of Andera Partners, the company managing BioDiscovery 5. BioDiscovery 5 is the direct beneficial owner of these securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.